Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 211

The DOI matches its Crossref record.

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

Open access
Gandara, David R., Kawaguchi, Tomoya, Crowley, John, Moon, James, Furuse, Kiyoyuki, Kawahara, Masaaki, Teramukai, Satoshi, Ohe, Yuichiro, Kubota, Kaoru, Williamson, Stephen K., Gautschi, Oliver, Lenz, Heinz Josef, McLeod, Howard L., Lara, Primo N., Coltman, Charles Arthur, Fukuoka, Masahiro, Saijo, Nagahiro, Fukushima, Masanori, Mack, Philip C.·2009·Journal of Clinical Oncology

Abstract

Purpose: To explore whether population-related pharmacogenomics contribute to differences in patient outcomes between clinical trials performed in Japan and the United States, given similar study designs, eligibility criteria, staging, and treatment regimens. Methods: We prospectively designed and conducted three phase III trials (Four-Arm Cooperative Study, LC00-03, and S0003) in advanced-stage, non–small-cell lung cancer, each with a common arm of paclitaxel plus carboplatin. Genomic DNA was collected from patients in LC00-03 and S0003 who received paclitaxel (225 mg/m 2) and carboplatin (area under the concentration-time curve, 6). Genotypic variants of CYP3A4, CYP3A5, CYP2C8, NR1I2-206, ABCB1, ERCC1, and ERCC2 were analyzed by pyrosequencing or by PCR restriction fragment length polymorphism. Results were assessed by Cox model for survival and by logistic regression for response and toxicity. Results: Clinical results were similar in the two Japanese trials, and were significantly different from the US trial, for survival, neutropenia, febrile neutropenia, and anemia. There was a significant difference between Japanese and US patients in genotypic distribution for CYP3A4*1B (P = .01), CYP3A5*3C (P = .03), ERCC1 118 (P < .0001), ERCC2 K751Q (P < .001), and CYP2C8 R139K (P = .01). Genotypic associations were observed between CYP3A4*1B for progression-free survival (hazard ratio [HR], 0.36; 95% CI, 0.14 to 0.94; P = .04) and ERCC2 K751Q for response (HR, 0.33; 95% CI, 0.13 to 0.83; P = .02). For grade 4 neutropenia, the HR for ABCB1 3425C→T was 1.84 (95% CI, 0.77 to 4.48; P = .19). Conclusion: Differences in allelic distribution for genes involved in paclitaxel disposition or DNA repair were observed between Japanese and US patients. In an exploratory analysis, genotype-related associations with patient outcomes were observed for CYP3A4*1B and ERCC2 K751Q. This common-arm approach facilitates the prospective study of population-related pharmacogenomics in which ethnic differences in antineoplastic drug disposition are anticipated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.20.8793

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 211

Metadata

Authors
Gandara, D. R., Kawaguchi, T., Crowley, J., Moon, J., Furuse, K., Kawahara, M., Teramukai, S., Ohe, Y., Kubota, K., Williamson, S. K., Gautschi, O., Lenz, H. J., McLeod, H. L., Lara, P. N., Coltman, C. A., Fukuoka, M., Saijo, N., Fukushima, M., & Mack, P. C.
Venue
Journal of Clinical Oncology
Published
2009-07-20
Volume
27
Issue
21
Pages
3540-3546
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2145238269
Cited by
211
References
0
FWCI
20.76
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics. https://app.cochat.ai/papers/10.1200/jco.2008.20.8793
The paper
Gandara, D. R., Kawaguchi, T., Crowley, J., Moon, J., Furuse, K., Kawahara, M., Teramukai, S., Ohe, Y., Kubota, K., Williamson, S. K., Gautschi, O., Lenz, H. J., McLeod, H. L., Lara, P. N., Coltman, C. A., Fukuoka, M., Saijo, N., Fukushima, M., & Mack, P. C. (2009). Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.20.8793

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.